Search

for
Search:

Did you mean Pyrilutamide?

Glossary Pyrilutamide

topical treatment blocking androgen receptors to combat hair loss

Pyrilutamide, also known as KX-826, is a topical non-steroidal anti-androgen being developed for the treatment of androgenetic alopecia (pattern hair loss). It works by blocking androgen receptors in hair follicles, which can help reduce hair loss and potentially promote hair regrowth.

Learn

1 / 2 results

learn Pyrilutamide

Experimental topical anti-androgen, also known as KX-826

What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT? Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp. Its sponsor reported that a 2023 China Phase III of a 0.5% tincture did not beat placebo and that a 2026 Phase III stage of a 1.0% tincture did; none of the data are peer-reviewed and it is not approved as a medicine anywhere.
Is pyrilutamide a safer alternative to oral antiandrogens like finasteride? Pyrilutamide (KX-826) is an unapproved, investigational topical antiandrogen whose safety data come from short-term sponsor announcements, not peer-reviewed studies. No study has compared it with finasteride, so there is no evidence that it is safer.
How long does it take to see visible results when using pyrilutamide topically? No published trial reports when pyrilutamide users first notice a change; its sponsor's studies measured results at 24 weeks, and all of those figures come from company announcements rather than peer-reviewed papers. Pyrilutamide is an unapproved experimental compound.
All 5 questions on Pyrilutamide →

View more "pyrilutimide" in learn →

Community Join

5 / 613 results

community Why is there so much negativity around pyrilutamide?

in Research/Science 19 upvotes 1 year ago

Pyrilutamide is discussed as an effective hair loss treatment by some users, despite skepticism due to limited data and underwhelming trial results. Users compare it to finasteride, minoxidil, and RU58841, with some expressing interest in its potential as an adjunct treatment.

community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

124 upvotes 2 years ago

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

community What I’ve learned From 8 Months on Pyrilutamide

11 upvotes 5 days ago

Pyrilutamide helps maintain hair density but is less effective than finasteride and needs consistent use. It works best with minoxidil, alfatrodial, and nizoral, though it is costly and inconvenient.

community Anyone having success with pyrilutamide?

5 upvotes 1 month ago

Pyrilutamide is being discussed for hair loss treatment, with one user reporting no success after six months and another using it alongside finasteride for two months. The conversation seeks recommendations and experiences with pyrilutamide.

community So why did the first pyrilutamide phase III fail?

4 upvotes 1 month ago

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

View more "pyrilutimide" in community →

Research

5 / 30 results

research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

1 citations , April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences”

This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.

research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms

1 citations , July 2022 in “JEADV Clinical Practice”

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia

July 2026 in “Figshare”

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia

July 2026 in “Figshare”

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia

July 2026 in “Figshare”

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

View more "pyrilutimide" in research →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →